Cellular and molecular effects of unoprostone as a BK channel activator

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 5, 2007, Pages 1083-1092

  Cuppoletti, John ^a   Malinowska, Danuta H ^a   Tewari, Kirti P ^a   Chakrabarti, Jayati ^a   Ueno, Ryuji ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Sucampo AG   (Switzerland)

Author keywords

Glaucoma; HCN 1A; IbTX; Latanoprost; Neuroprotection; PGF2

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; GLUTAMIC ACID; IBERIOTOXIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LATANOPROST; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; TAMOXIFEN; UNCLASSIFIED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ARTICLE; CALCIUM TRANSPORT; CELL MEMBRANE; CELL POLARITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MEMBRANE DEPOLARIZATION; MOLECULAR DYNAMICS; NEUROPROTECTION; PRIORITY JOURNAL; PROTEOMICS; SIGNAL TRANSDUCTION;

ANTIHYPERTENSIVE AGENTS; CALCIUM; CALIBRATION; CELL LINE; CHELATING AGENTS; CHLORIDE CHANNELS; DINOPROST; GLUTAMIC ACID; HUMANS; ION CHANNEL GATING; MEMBRANE POTENTIALS; PEPTIDES; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN; TAMOXIFEN;

EID: 34047253753     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.12.015     Document Type: Article

References (50)

1. M.A. Kass, D.K. Heuer, E.J. Higginbotham, C.A. Johnson, J.L. Keltner, J.P. Miller, R.K. Garrish 2nd, W.R. Wilson, M.O. Gordon, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120 (2002) 701-713 and 829-830.
2. Melamed S. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: clinical benefits in the treatment of glaucoma. Drugs Exp. Clin. Res. 28 (2002) 63-73
3. Thieme H., Stumpff F., Ottlecz A., Percicot C.L., Lambrou G.N., and Wiederholt M. Mechanisms of action of unoprostone on trabecular meshwork contractility. Invest. Ophthalmol. Vis. Sci. 42 (2001) 3193-3201
4. Yoshitomi T., Yamaji K., Ishikawa H., and Ohnishi Y. Vasodilatory mechanism of unoprostone isopropyl on isolated rabbit ciliary artery. Curr. Eye Res. 28 (2004) 167-174
5. Thieme H., Steinhausen K., Ottlecz A., Lambrou G.N., Strauss O., Wiederholt M., and Rosenthal R. Effects of unoprostone and endothelin 1 on L-type channel currents in human trabecular meshwork cells. Ophthalmic Res. 37 (2005) 293-300
6. 2+ currents in cultured monkey trabecular meshwork cells and ciliary muscle cells. J. Ocular Pharmacol. Ther. 22 (2006) 219-226
7. Linden C. Therapeutic potential of prostaglandin analogues in glaucoma. Expert Opin. Investig. Drugs 10 (2001) 679-694
8. Stewart W.C., Kolker A.E., Sharpe E.D., Day D.G., Holmes K.T., Leech J.N., Johnson N., and Cantrell J.B. Factors associated with long-term progression or stability in primary open-angle glaucoma. Am. J. Ophthalmol. 130 (2000) 274-279
9. Tezel G., Siegmund K.D., Trinkaus K., Wax M.B., Kass M.A., and Kolker A.E. Clinical factors associated with progression of glaucomatous optic disc damage in treated patients. Arch. Ophthalmol. 119 (2001) 813-818
10. Flammer J., Haefliger I.O., Orgul S., and Resink T. Vascular dysregulation: a principal risk factor for glaucomatous damage?. J. Glaucoma 8 (1999) 212-219
11. 2+ influx and cell death in retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 42 (2001) S750
12. Ogawa I., and Imai K. Comparison of visual fields in eyes with normal-tension glaucoma during 4-year periods of treatment with unoprostone followed by latanoprost. Folia Ophthalmol. Jpn. 55 (2004) 740-746
13. Ogawa I., and Imai K. Long-term effects on visual fields of unoprostone for normal-tension glaucoma. Folia Ophthalmol. Jpn. 54 (2003) 571-577
14. Takeuchi K., Ohguro I., Ohguro H., and Nakazawa M. Neuroprotective effects of anti-glaucoma eye drops studied by frequency doubling technology. Ganka 47 (2005) 889-894
15. Ishida T., Yamada Y., Katayama T., Koshibu A., and Yamashita I. Topical monotherapy for normal tension glaucoma. Ganka 47 (2005) 1107-1112
16. Iida N., Yamazaki Y., Ito L., Omata T., Yajima T., Takei A., and Hamanaka T. The effect of isopropyl unoprostone on visual field loss in patients with primary open angle glaucoma. Jpn. Rev. Clin. Ophthalmol. 99 (2005) 707-709
17. Mukuno H., Nakamura M., Kanamori A., Nagai A., Negi A., and Seigel G. Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro. Curr. Eye Res. 29 (2004) 457-464
18. Hayami K., and Unoki K. Photoreceptor protection against constant light-induced damage by isopropyl unoprostone, a prostaglandin F(2alpha) metabolite-related compound. Ophthalmic Res. 33 (2001) 203-209
19. 2+ homeostasis and mitochondrial dysfunction in mammalian central neurons. Prog. Biophys. Mol. Biol. 86 (2004) 279-351
20. 3+ in cultured cortical neurons. J. Neurochem. 91 (2004) 471-483
21. Simard J.M., Song Y., Tewari K., Dunn S., Werrbach-Perez K., Perez-Polo J.R., and Eisenberg H.M. Ionic channel currents in cultured neurons from human cortex. J. Neurosci. Res. 34 (1993) 170-178
22. Gribkoff V.K., Lum-Ragan J.T., Boissard C.G., Post-Munson D.J., Meanwell N.A., Starrett Jr. J.E., Kozlowski E.S., Romine J.L., Trojnacki J.T., Mckay M.C., Zhong J., and Dworetzky S.I. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol. Pharmacol. 50 (1996) 206-217
23. Gribkoff V.K., Starrett Jr. J.E., Dworetzky S.I., Hewawasam P., Boissard C.G., Cook D.A., Frantz S.W., Heman K., Hibbard J.R., Huston K., Johnson G., Krishnan B.S., Kinney G.G., Lombardo L.A., Meanwell N.A., Molinoff P.B., Myers R.A., Moon S.L., Ortiz A., Pajor L., Pieschl R.L., Post-Munson D.J., Signor L.J., Srinivas N., Taber M.T., Thalody G., Trojnacki J.T., Wiener H., Yeleswaram K., and Yeola S.W. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. 7 (2001) 471-477
24. Jensen B.S. BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev. 8 (2002) 353-360
25. Hong K.W., Kim K.Y., Shin H.K., Lee J.H., Choi J.M., Kwak Y.G., Kim C.D., Lee W.S., and Rhim B.Y. Cilostazol prevents tumor necrosis factor-alpha-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J. Pharmacol. Exp. Ther. 306 (2003) 1182-1190
26. 2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J. Pharmacol. Exp. Ther. 304 (2003) 238-245
27. 2+ mobilization and MAP kinase activation. J. Ocular Pharmacol. Ther. 19 (2003) 437-455
28. Sharif N.A., Kelly C.R., Crider J.Y., Williams G.W., and Xu S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocular Pharmacol. Ther. 19 (2003) 501-515
29. Sharif N.A., Kelly C.R., and Crider J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 44 (2003) 715-721
30. Kashiwagi K., Iizuka Y., and Tsukahara S. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits. Jpn. J. Pharmacol. 81 (1999) 56-62
31. Bhattacherjee P., Paterson C.A., and Percicot C. Studies on receptor binding and signal transduction pathways of unoprostone isopropyl. J. Ocular Pharmacol. Ther. 17 (2001) 433-441
32. Frieling T., Rupprecht C., Dobreva G., Haussinger D., and Schemann M. Effects of prostaglandin F2 alpha (PGF2 alpha) and prostaglandin I2 (PGI2) on nerve-mediated secretion in guinea-pig colon. Pflugers Arch. 431 (1995) 212-220
33. - conductance. J. Cell. Physiol. 170 (1997) 166-173
34. - channels: homing in on an elusive channel species. Prog. Neurobiol. 60 (2000) 247-289
35. Gruber A.D., Schreur K.D., Ji H.L., Fuller C.M., and Pauli B.U. Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland. Am. J. Physiol. 276 (1999) C1261-C1270
36. - currents. Am. J. Physiol., Cell Physiol. 287 (2004) C1173-C1183
37. - currents regulate steady-state and dynamic membrane potentials in cultured rat microglia. J. Physiol. 567 (2005) 869-890
38. + channels as modulators of human myometrial contractile activity. Am. J. Physiol. 265 (1993) C976-C985
39. Epps D.E., Wolfe M.L., and Groppi V. Characterization of the steady-state and dynamic fluorescence properties of the potential-sensitive dye bis-(1,3-dibutylbarbituric acid)trimethine oxonol (DiBAC4(3)) in model systems and cells. Chem. Phys. Lipids 69 (1994) 137-150
40. + channels in HEK293 cells. Jpn. J. Pharmacol. 86 (2001) 342-350
41. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985) 3440-3450
42. Rego A.C., Santos M.S., and Oliveira C.R. Oxidative stress, hypoxia, and ischemia-like conditions increase the release of endogenous amino acids by distinct mechanisms in cultured retinal cells. J. Neurochem. 66 (1996) 2506-2516
43. Portzehl H., Caldwell P.C., and Ruegg J.C. The dependence of contraction and relaxation of muscle fibres from the crab Maia 8quinado on the internal concentration of free calcium ions. Biochim. Biophys. Acta 79 (1964) 581-591
44. 2+ chelator. Biochim. Biophys. Acta 983 (1989) 82-90
45. Duncan R.K. Tamoxifen alters gating of the BK alpha subunit and mediates enhanced interactions with the avian beta subunit. Biochem. Pharmacol. 70 (2005) 47-58
46. - channel function and cell volume regulation in AGS cells. Am. J. Physiol.: Gasterointest. Liver Physiol. 285 (2003) G938-G948
47. Sjorquist B., and Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv. Ophthalmol. 47 (2002) S6-S12
48. Osborne N.N., Chidlow G., and Wood J.P. Glutamate excitotoxicity in glaucoma: truth or fiction? by AJ Lotery. Eye (2006) 1-2
49. Osborne N.N., Melena J., Chidlow G., and Wood J.P. A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma. Br. J. Ophthalmol. 85 (2001) 1252-1259
50. i by antiglaucoma drugs in cultured A7r5 vascular smooth-muscle cells. J. Ocular Pharmacol. Ther. 20 (2004) 201-209